Investors are keeping a close eye on Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) after director John P. Schmid increased his stake in the company by purchasing additional shares. The transaction, valued at $9,720, took place on March 14, according to recent filings with the Securities and Exchange Commission.
Schmid acquired 4,500 shares of common stock at a price of $2.16 per share, bringing his total ownership to 11,000 shares held indirectly by The Schmid Family Trust. This move by a member of the company’s board is often seen as a sign of confidence in the company’s future.
Xeris Biopharma Holdings, based in Chicago, Illinois, specializes in pharmaceutical preparations. The company has not issued any statements regarding the transaction, but investors and market watchers are closely monitoring insider activity for insights into the company’s value and potential.
Market participants are evaluating Xeris Biopharma’s financial health and future prospects, especially with recent performance data and analyst insights from InvestingPro. The company has a negative Price/Earnings ratio and challenges in converting revenues to operating income, but has shown revenue growth.
InvestingPro Tips suggest caution due to the stock being in oversold territory and analysts revising earnings expectations downwards. Despite a high return over the last year, the stock has performed poorly in the last month. Investors can access additional insights on the company’s financials and forecasts through InvestingPro.
For those interested in comprehensive investment analysis, a limited-time discount is available on InvestingPro subscriptions using the coupon code PRONEWS24. This news story was generated with the support of AI and reviewed by an editor.
